Buphenine: Difference between revisions
Appearance
Content deleted Content added
ce |
Citation bot (talk | contribs) Alter: pages. Add: pmid, doi, issue, s2cid. Formatted dashes. | Use this bot. Report bugs. | Suggested by Headbomb | #UCB_toolbar |
||
Line 42: | Line 42: | ||
}} |
}} |
||
'''Buphenine''' (or '''nylidrin'''; trade name '''Arlidin''') is a [[Beta2-adrenergic agonist|β<sub>2</sub> adrenoreceptor agonist]]<ref name="pmid2857689">{{cite journal |vauthors=Mittag TW, Tormay A, Messenger M, Podos SM |title=Ocular hypotension in the rabbit. Receptor mechanisms of pirbuterol and nylidrin |journal=Invest Ophthalmol Vis Sci |volume=26 |issue=2 |pages=163–9 |date=February 1985 |pmid=2857689 |url=http://www.iovs.org/cgi/pmidlookup?view=long&pmid=2857689 |url-status=dead |archiveurl=https://archive.today/20130415011509/http://www.iovs.org/cgi/pmidlookup?view=long&pmid=2857689 |archivedate=2013-04-15 }}</ref> that acts as a [[vasodilator]].<ref>{{cite journal| vauthors=Freedman L| title=Arlidin: a new vasodilative sympathomimetic drug | journal=Angiology | year= 1955 | volume= 6 | issue= 1 | pages= |
'''Buphenine''' (or '''nylidrin'''; trade name '''Arlidin''') is a [[Beta2-adrenergic agonist|β<sub>2</sub> adrenoreceptor agonist]]<ref name="pmid2857689">{{cite journal |vauthors=Mittag TW, Tormay A, Messenger M, Podos SM |title=Ocular hypotension in the rabbit. Receptor mechanisms of pirbuterol and nylidrin |journal=Invest Ophthalmol Vis Sci |volume=26 |issue=2 |pages=163–9 |date=February 1985 |pmid=2857689 |url=http://www.iovs.org/cgi/pmidlookup?view=long&pmid=2857689 |url-status=dead |archiveurl=https://archive.today/20130415011509/http://www.iovs.org/cgi/pmidlookup?view=long&pmid=2857689 |archivedate=2013-04-15 }}</ref> that acts as a [[vasodilator]].<ref>{{cite journal| vauthors=Freedman L| title=Arlidin: a new vasodilative sympathomimetic drug | journal=Angiology | year= 1955 | volume= 6 | issue= 1 | pages= 52–8 | pmid=14350296 | doi=10.1177/000331975500600106| s2cid=46317963 }}</ref> |
||
It was developed as a chemical derivative of [[oxilofrine]], and first reported in the literature in 1950.<ref>{{cite journal| vauthors=Külz F, Schneider M| title=Über neue gefäßerweiternde Sympathomimetika |language=German |trans-title=On new vasodilative sympathomimetics | journal=Klin Wochenschr | year= 1950 | volume= 28 | pages= |
It was developed as a chemical derivative of [[oxilofrine]], and first reported in the literature in 1950.<ref>{{cite journal| vauthors=Külz F, Schneider M| title=Über neue gefäßerweiternde Sympathomimetika |language=German |trans-title=On new vasodilative sympathomimetics | journal=Klin Wochenschr | year= 1950 | volume= 28 | issue=31–32 | pages= 535–7| doi=10.1007/BF01481535 | pmid=14775050 }}</ref> |
||
==See also== |
==See also== |
Revision as of 08:12, 11 July 2022
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.006.531 |
Chemical and physical data | |
Formula | C19H25NO2 |
Molar mass | 299.414 g·mol−1 |
3D model (JSmol) | |
|
Buphenine (or nylidrin; trade name Arlidin) is a β2 adrenoreceptor agonist[1] that acts as a vasodilator.[2]
It was developed as a chemical derivative of oxilofrine, and first reported in the literature in 1950.[3]
See also
References
- ^ Mittag TW, Tormay A, Messenger M, Podos SM (February 1985). "Ocular hypotension in the rabbit. Receptor mechanisms of pirbuterol and nylidrin". Invest Ophthalmol Vis Sci. 26 (2): 163–9. PMID 2857689. Archived from the original on 2013-04-15.
- ^ Freedman L (1955). "Arlidin: a new vasodilative sympathomimetic drug". Angiology. 6 (1): 52–8. doi:10.1177/000331975500600106. PMID 14350296. S2CID 46317963.
- ^ Külz F, Schneider M (1950). "Über neue gefäßerweiternde Sympathomimetika" [On new vasodilative sympathomimetics]. Klin Wochenschr (in German). 28 (31–32): 535–7. doi:10.1007/BF01481535. PMID 14775050.